We compared the efficacy of the prokinetic agent cisapride with that of Gaviscon (an alginate/alkaline compound) plus Carobel
(carob seed flour) in the treatment of gastrooesophageal reflux (GOR). Fifty infants with confirmed GOR received either oral cisapride (0-8 mg/kg/day) or Gaviscon plus Carobel for one month in a randomised, parallel group study. Parental evaluations, diary scores, and 24 hour lower oesophageal pH recordings before and at the end of each treatment were compared.
In the cisapride group 14/26 (53%) were considered better by their parents compared with 19/24 (79%) of those who received Gaviscon plus Carobel. Diary scores, range (0-00-1-00), improved in both groups with the median change being greater in the Gaviscon plus Carobel group (-0-21) than the cisapride group (-0-15) . Five of 17 pH variables had significantly improved from baseline in infants who had received cisapride compared with 11/17 in those receiving Gaviscon plus Carobel. However, unpaired analysis of diary and pH data showed no significant differences between the two groups. We conclude that first line treatment of GOR with cisapride is no more effective than conventional treatment with Gaviscon plus Carobel. feeds more viscous, making regurgitation less likely. In the present study the relative effectiveness of Gaviscon plus Carobel and cisapride in infants with symptomatic GOR is assessed. We report our findings in a randomised, parallel group trial conducted over a one month period utilising both clinical criteria and lower oesophageal pH monitoring.
Patients and methods

PATIENTS
Fifty bottle fed infants with chronic vomiting, aged between 2 and 18 months, had GOR confirmed by 24 hour lower oesophageal pH monitoring (that is, a pH less than 4 for at least 5% of the recording period). None Strobel et al. 12 The semidisposable electrodes were calibrated before and after each test at pH 1 and 7 at 23°C. Electrodes were discarded if deviations of 0-2 pH units or more from either standard buffer occurred. A reusable silver/silver chloride reference electrode model 4011 (Synectics Medical) was secured to the chest wall and both electrodes were attached to a portable pH recorder and data storage system (Digitrapper Mark II, Synectics) which sampled intraoesophageal pH every four seconds. A reflux episode was defined as a fall in pH to below 4 for 15 seconds or longer. The lightweight device was easily carried by parents in a shoulder bag. No restrictions were placed on activity or diet during the 24 hour study period. On completion of each study the stored data were transferred on to an Amstrad PC 1512. Using dedicated software 'EsopHogram' (Gastrosoft Inc) the following variables were computed: (i) number of reflux episodes, (ii) number of reflux episodes >5 minutes, (iii) the longest reflux episode, and (iv) the percentage of the time during which reflux occurred, also known as the 'reflux index'. These were calculated for postprandial periods (within two hours of a feed), fasting periods (two hours or more after feeding), overnight (10 pm-6 am), and the total recording time. The total number of episodes and the number of episodes >5 minutes were expressed as an average rate per hour to allow for individual variations in the number and duration of feeds. Acid clearance values for postprandial and fasting periods were also calculated and expressed as minutes per reflux episode. LRE-longest reflux episode.
STATISTICAL METHODS
Contingency tables were constructed and x2 tests with Yates's correction factor were employed to determine the significance of differences in parental assessment between the two treatments. As the ages of infants, diary scores, and pH variables were not normally distributed non-parametric tests were employed. Changes in pH variables after treatment were analysed using Wilcoxon signed rank tests and significance was defined as p<0 05 . Median values were calculated for pH variables. Differences between the two groups were assessed using the Mann-Whitney U test.
Results
All 50 infants completed the study. Twenty six had received cisapride (group A) and 24 Gaviscon (group B). Twenty one of the latter group were also given Carobel (1-2 scoops to each 90 ml feed). A double blind design was not feasible for two reasons: first, to achieve the therapeutic effect at the desired time it was necessary to administer cisapride at least 30 minutes before a meal, whereas Gaviscon and Carobel had to be given during or after food. Second, there were differences in formulation that could not be overcome. Cisapride was only available as a liquid suspension and had to be given directly to the child, whereas Gaviscon and Carobel were in powder form and had to be mixed with the infant's formula at the time of feeding.
In pH terms, the best indicators of motility are the number of reflux episodes >5 minutes, the longest reflux episode, and the acid clearance time. The improvements seen in the number of reflux episodes >5 minutes and the longest reflux episode in the cisapride group during the fasting period are in agreement with other studies that demonstrate a prominent motility effect in the fasting period.6 Cisapride's apparent lack of effect when the stomach is full is believed to be due to an increase in the frequency and duration of lower oesophageal sphincter (LOS) relaxations that result in more frequent reflux episodes. 3 The more rapid acid clearance values seen in the postprandial period of patients receiving cisapride suggest an early improvement in oesophageal motility. Phasic LOS relaxations are putatively responsible for the majority of reflux episodes, but low basal tone accounts for 20% of episodes'4 and becomes more important as oesophagitis progresses.'5 Motility studies in vomiting infants have shown that cisapride improves LOS tone6 but concurrent pH studies in such infants failed to show a reduction in the number of reflux episodes, which reflects the degree of competence of the LOS. In the present study, no significant effect on the number of reflux episodes was observed in patients who received either treatment.
GOR occurs less frequently in the sleeping state than in wakefulness,'6 but the degree of overnight reflux may be predictive for the development of stricture and the need for antireflux surgery.'7 Gaviscon plus Carobel reduced these overnight measures of GOR severity considerably (table 3) whereas the changes achieved by cisapride were not significant.
One difficulty in interpreting the results of pH studies in infants with GOR is the buffering effect of milk on acid resulting in neutral reflux. Some investigators have overcome this problem by acidifying feeds during the test period. This is not feasible in any study with Gaviscon because acid added to feeds would have been neutralised by the alginate/alkali compound. The mechanism(s) whereby Gaviscon exerts a therapeutic effect is not fully known. It produces a viscous raft on the surface of gastric contents protecting the oesophagus from acid reflux. However, a recent study has shown that Gaviscon must be taken 30 minutes after food for raft formation to occur.'8 It did not occur when the drug was taken before or with a meal. Moreover, Laitinen et al have shown that sucralfate and Gaviscon taken 30 minutes before meals (when raft formation is unlikely) relieved symptoms and healed oesophagitis. ' We wish to thank Janssen Pharmaceuticals for providing generous financial support, the paediatricians at Leicester Royal Infirmary for referring patients and, not least, the parents who volunteered their children for this study.
